Mucosal Vaccine Adjuvants: Current Challenges and Emerging Strategies
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".
Deadline for manuscript submissions: 31 January 2027 | Viewed by 238
Special Issue Editor
Interests: characterization of the mucosal immune response against pathogens and commensals; development of commensal-derived and heat-resistant mucosal adjuvants and unitemporal vaccines; characterization of the immune response, particularly the mucosa in chronic low-grade inflammation: stress; obesity; alcoholism; immunosenescence; infertility and diabetes; vaccine immune response in atopics and in critical stages of life: premature babies; low birth weight; children who did not breastfeed, born by cesarean section and senescence; development of study programs, means and evaluative technologies for undergraduate and postgraduate teaching in immunology for science; immune response to vaccines and drugs against COVID-19
Special Issue Information
Dear Colleagues,
Most infectious arrive at, establish, or traverse mucosal surfaces, which requires mucosal approaches. In contrast, most vaccines are parenteral, which does not induce mucosal protection. Vaccine formulations require mucosal adjuvants to overcome tolerance-inducing systemic and mucosal (resident T, CD4+, and CD8+, and B memory) immune responses. Our hope is this Special Issue on vaccines will review the challenges and emerging strategies to obtain safe, heat-resistant, cross-reactive, and, among others things, mucosal vaccine adjuvants.
Prof. Dr. Oliver Peŕez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adjuvants
- vaccines
- mucosal immune responses
- allergic response
- immunology
- glycans
- lipids
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
